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Key questions
What is already known about this subject?
 ► There is strong scientific evidence that lifestyle, 
risk factor and therapeutic management of patients 
with CHD will reduce their risk of subsequent events 
and increase survival. The Joint British Societies’ 
Consensus Recommendations for the Prevention of 
Cardiovascular Disease guidelines summarise this 
scientific evidence for secondary prevention and 
the British Association for Cardiovascular Prevention 
and Rehabilitation advocate standards for cardio-
vascular disease prevention and rehabilitation.
What does this study add?
 ► ASPIRE-3- PREVENT provides a contemporary pic-
ture of the implementation of the guidelines and 
standards in everyday clinical practice across the 
UK and quantifies the scope for improvement.
How might this impact on clinical practice?
 ► These results will inform commissioners of services 
about the need to improve delivery of secondary pre-
ventive care and how this can be achieved through a 
modern preventive cardiology programme.
AbstrAct
Objective To quantify the implementation of the third 
Joint British Societies’ Consensus Recommendations for 
the Prevention of Cardiovascular Disease (JBS3) after 
coronary event.
Methods Using a cross- sectional survey design, patients 
were consecutively identified in 36 specialist and district 
general hospitals between 6 months and 2 years, after 
acute coronary syndrome or revascularisation procedure 
and invited to a research interview. Outcomes included 
JBS3 lifestyle, risk factor and therapeutic management 
goals. Data were collected using standardised methods 
and instruments by trained study nurses. Blood was 
analysed in a central laboratory and a glucose tolerance 
test was performed.
Results 3926 eligible patients were invited to participate 
and 1177 (23.3% women) were interviewed (30% 
response). 12.5% were from black and minority ethnic 
groups. 45% were persistent smokers, 36% obese, 52.9% 
centrally obese, 52% inactive; 30% had a blood pressure 
>140/90 mm Hg, 54% non- high- density lipoprotein 
≥2.5 mmol/L and 44.3% had new dysglycaemia. 
Prescribing was highest for antiplatelets (94%) and statins 
(85%). 81% were advised to attend cardiac rehabilitation 
(86% <60 years vs 79% ≥60 years; 82% men vs 77% 
women; 93% coronary artery bypass grafting vs 59% 
unstable angina), 85% attended if advised; 69% attended 
overall. Attenders were significantly younger (p=0.03) and 
women were less likely to attend (p=0.03).
Conclusions Patients with coronary heart disease 
(CHD) are not being adequately managed after event 
with preventive measures. They require a structured 
preventive cardiology programme addressing lifestyle, risk 
factor management and adherence to cardioprotective 
medications to achieve the standards set by the 
British Association for Cardiovascular Prevention and 
Rehabilitation and JBS3 guidelines.
IntROduCtIOn
ASPIRE-3- PREVENT (A-3- P)1 2 was conducted 
to evaluate preventive care for patients with 
coronary heart disease (CHD) in everyday 
clinical practice. Goals for care were outlined, 
most recently, in the Joint British Socie-
ties’ Consensus Recommendations for the 
Prevention of Cardiovascular Disease (JBS3)3 
and aim to reduce morbidity, improve quality 
of life and increase life expectancy. A-3- P was 
conducted as part of the fifth EUROASPIRE 
survey, which investigated preventive care 
in patients with CHD from 27 European 
countries. The European Society of Cardi-
ology (ESC) EUROASPIRE cross- sectional 
surveys4–8 have repeatedly evaluated imple-
mentation of the European prevention guide-
lines since 1995.
There is substantial evidence that inter-
vening to modify adverse lifestyle behaviours 
and manage medical risk factors can reduce 
the risk of future cardiovascular events and 
improve survival in patients with CHD.3 9–11 
Opportunities for delivering quality care for 
this patient group are offered by compre-
hensive cardiovascular prevention and 
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box 1 Outcome measures and research instruments for the 
ASPIRE-3- PREVENT (A-3- P) survey
 ► Current smoking validated with a breath carbon monoxide (CO) test 
≥10 ppm (Micro+Smokerlyzer, Bedfont Scientific, Kent, UK).
 ► Persistent smoking: smoking at recruiting event and still smoking 
at interview.
 ► Overweight26 27: body mass index (BMI) ≥25 kg/m2 (non- Asian); 
BMI ≥23 kg/m2 (Asian) (height and weight measured in light indoor 
clothes without shoes with SECA measuring stick model 220 and 
SECA scale model 701).
 ► Obesity26 27: BMI ≥30 kg/m2 (non- Asian); BMI ≥25 kg/m2 (Asian).
 ► Central overweight26 27: waist circumference (WC) ≥94 cm (non- 
Asian men); WC ≥90 cm (Asian men); WC ≥80 cm (all women) (WC 
measured with metal tape measures mid- way between the lower 
rib margin and the iliac crest).
 ► Central obesity26 27: WC ≥102 cm (non- Asian men); WC ≥90 cm 
(Asian men); WC ≥88 cm (non- Asian women); WC ≥80 cm (Asian 
women).
 ► Not performing moderate- intensity physical activity at least 30 min/5 
times per week (Godin Leisure- Time Exercise Questionnaire28).
 ► Elevated blood pressure: ≥140 mm Hg and/or ≥90 mm Hg (blood 
pressure measured twice on the right upper arm in a sitting position 
after rest for at least 5 min using Omron M6 HEM 7211- E automatic 
digital sphygmomanometers).
 ► Non- high- density lipoprotein (HDL) cholesterol: ≥2.5 mmol/L (anal-
ysed in central laboratory in Finland).
 ► Low- density lipoprotein cholesterol (LDL- C) ≥1.8 mmol/L.
 ► HbA1c ≥7% (≥53 mmol/mol) in patients with type 2 diabetes 
mellitus.29
 ► New diabetes mellitus (DM); impaired fasting glycaemia (IFG); 
impaired glucose tolerance (IGT) from oral glucose tolerance test 
(OGTT) (see box 230) in patients without self- reported diabetes and 
with fasting blood glucose (FBG) <11.1 mmol/L measured with 
HemoCue near- patient testing monitor.
 ► Cardiovascular drug therapies and medication adherence.31
 ► Hospital Anxiety and Depression Scale (HADS32), HeartQoL,33 
EuroQoL (EQ- 5D34).
rehabilitation programmes. In the third edition of their 
standards and core components,12 the British Associa-
tion for Cardiovascular Prevention and Rehabilitation 
(BACPR) place emphasis on the need to underpin 
cardiovascular disease (CVD) risk reduction with patient- 
centred, behavioural and goal- oriented approaches to 
address risk factor and therapeutic management with 
timely intervention from a clinically led multidisciplinary 
team. Audit of outcomes is through the National Audit 
for Cardiac Rehabilitation’s (NACR)13 latest report 2018.
The specific objectives of this survey were:
 ► To determine adherence to JBS3 guidelines in 
everyday clinical practice for patients with CHD.
 ► To evaluate diagnostic and therapeutic strategies for 
dysglycaemia.
 ► To make recommendations to the BACPR, British 
Cardiovascular Society and Public Health England on 
ways to improve preventive cardiology care.
This paper describes the principal results of A-3- P in 
relation to achievement of lifestyle, risk factor and thera-
peutic targets as defined in the JBS3 guidelines.
MetHOds
A-3- P was registered as a cross- sectional survey with the 
National Institute for Health Research Clinical Research 
Network (CRN) Portfolio on 23 August 2016 and made 
visible to all CRNs in England wishing to participate. It 
aimed to secure representation from hospital centres 
across five English National Health Service regions and 
in CRNs in Wales, Northern Ireland and Scotland. Thir-
ty- six specialist cardiac centres and district general hospi-
tals were recruited in this convenience sample.
Fieldwork for the survey was led by CRN and hospital 
Research and Development (R&D) department nurses. 
Hospitals were asked to create lists of retrospectively iden-
tified eligible patients from their clinical coding systems 
and to recruit consecutively according to admission date 
for the recruiting event. Eligibility was defined as male 
and female patients between the ages of 18 and 79 years at 
the time of diagnosis with new or recurrent ST- elevation 
myocardial infarction (STEMI), non- STEMI (NSTEMI) 
or acute ischaemia and/or elective or emergency percu-
taneous coronary intervention (PCI) or coronary artery 
bypass grafting (CABG). Patients were entered onto an 
electronic log and invited to participate, where reason 
for non- participation was also recorded. Patients were 
invited to attend an interview and examination with the 
centrally trained nurses who obtained written, informed 
consent, collected data using standardised instruments 
and methods (see box 1), and drew blood, processed and 
stored it prior to it being sent to the central laboratory 
in Finland for analysis. Outcome measures can be seen 
in box 1. Data were entered and managed on the anony-
mised ESC EurObservational Research Programme elec-
tronic online database.
A sample size of 400 patients attending for interview was 
sufficient with a precision of at least 5% and a confidence 
of 95% to estimate prevalence and allow power to stratify 
by age and gender and to estimate prevalence of single 
risk factors with 95% CIs of width 10%. All statistical anal-
yses were undertaken using STATA V.11 (StataCorp). The 
majority of analyses were descriptive aiming to summarise 
characteristics and outcomes. The exact binomial method 
was used to calculate CIs for the percentage values. The 
McNemar test was used to statistically compare the results 
from hospital discharge and the time of interview for the 
proportion of patients on the most popular medications.
The cardiac rehabilitation (CR) analyses focused on 
differences in patients who were advised and not advised 
and who attended and did not attend a programme. 
Attendance was defined as one or more of the programme 
sessions. The groups were compared on key demo-
graphic variables and comparisons between the groups 
were made for lifestyle, risk factors and prescribing. All 
outcomes were binary and comparisons between groups 
were made using logistic regression. Adjustments were 
made if results varied in terms of key demographics.
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box 2 Diagnostic criteria for diabetes and dysglycaemia
diabetes ☐ No ☐ Yes
Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL)
or
2- hour plasma glucose* ≥11.1 mmol/L (200 mg/dL)
Impaired glucose tolerance (IGt) ☐ No ☐ Yes
Fasting plasma glucose <7.0 mmol/L (<126 mg/dL)
and 2- hour glucose* ≥7.8 and <11.1 mmol/L (140 and <200 mg/dL)
Impaired fasting glucose (IFG) ☐ No ☐ Yes
Fasting plasma glucose ≥6.1 and <6.9 mmol/L (110 and <125 
mg/dL)
and 2- hour plasma glucose* <7.8 mmol/L (140 mg/dL)
*Venous plasma glucose 2 hours after the ingestion of 75 g dissolved glucose 
in 200 mL water.
Figure 1 Flow chart of patients through all phases of data 
collection in ASPIRE-3- PREVENT. CABG, coronary artery 
bypass grafting; NSTEMI, non- STEMI; OGTT, oral glucose 
tolerance test; PTCA, percutaneous transluminal coronary 
angioplasty; STEMI, ST- elevation myocardial infarction.
Results
Figure 1 shows the flow of patients through the study. 
Non- attendance at interview was driven principally by a 
failure to respond to the invitation (71% of DNA). As 
expected in a population of patients with CHD under the 
age of 80 years, the majority were male (77%). The mean 
age of the participants was 65.7 years and most were of 
white ethnicity. Nearly two- thirds of patients identified 
for the study had either acute STEMI or NSTEMI.
Table 1 shows lifestyle habits, medical risk factors, 
prescribing and psychosocial status in all patients and 
also according to their attendance at a CR programme. 
If adhering to national standards (BACPR), CR should 
have been offered to all patients who have suffered a 
cardiac event and/or who have been revascularised, that 
is, all those who were recruited to this survey. In fact, a 
large proportion of interviewed patients (80.8%) were 
advised to attend a programme and, of these, 84.8% 
attended. Out of all 1177 patients, 68.5% attended a 
programme. Patients most likely to be advised were those 
who had undergone CABG. Least advised were patients 
with unstable angina, older patients, women, those not 
achieving the physical activity target and those with 
self- reported diabetes. Interestingly, less advised groups 
were just as likely to attend if so advised (see table 2). 
There were significant differences between patients who 
attended and did not attend in relation to mean age 
(66.6 years in non- attenders compared with 65.4 years in 
attenders, p=0.03), gender and revascularisation proce-
dure (see table 2) with women and older patients being 
less likely to attend and those revascularised with CABG 
and acute myocardial infarction being more likely to 
attend.
tobacco
Around one- fifth reported smoking at the time of their 
event (table 1) and nearly one- half of these were still 
smoking at the time of interview. There were no statis-
tical differences between men and women with regard 
to smoking habit. Among current smokers, two- thirds 
reported an intention to quit within the next 6 months. 
There were no gender differences.
While the majority of current smokers or recent quit-
ters reported being advised to quit since the recruiting 
cardiac event, only a minority were advised to use phar-
macological support or referred for specialist help (see 
table 3). At the time of discharge from hospital, around 
one- fifth of current smokers and recent quitters were 
prescribed antismoking treatments (table 4). Around 
two- thirds of patients made a quit attempt although a 
relatively small proportion accessed specialist support or 
pharmacotherapies. Current smokers were significantly 
less likely to attend a CR programme.
Overweight and obesity
A large majority of patients were above ideal body mass 
index (table 1). More than half were centrally obese 
with a significantly higher prevalence in women. There 
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were no significant differences in prevalence according 
to attendance at CR. Two- thirds of overweight patients 
reported being advised to lose weight and attempted to 
do so.
Physical activity and exercise
Approximately one- half reported not achieving the phys-
ical activity recommendation (see table 1). However, 
40%, mostly women, reported having a disability of which 
the majority said limited exercise capacity (see table 3). 
Around one- half claimed to take regular planned exer-
cise (see figure 2).
Biological risk factors
One- third had raised blood pressure (BP) according 
to the JBS3 goal (<140 and/or 90 mm Hg) (table 1). 
However, if more recent guidelines on BP targets from the 
American Heart Association/American College of Cardi-
ology14 and the ESC/European Society of Hypertension15 
are taken into account, this proportion is higher with 
nearly 60% of patients having a BP of ≥130 mm Hg and/
or ≥80 mm Hg. More than one- half of patients are not 
reaching the JBS3 non- high- density lipoprotein choles-
terol (HDL- C) goal of 2.5 mmol/L and these prevalences 
are significantly higher in women. While one- quarter of 
patients reported having been previously diagnosed with 
diabetes, an oral glucose tolerance test (OGTT) picked 
up new dysglycaemia in a further 44% of patients (see 
figure 3). 39.7% of patients with self- reported diabetes 
had a BP <130 mm Hg and/or <80 mm Hg and 50.9% an 
HbA1c of <7% (<53 mmol/mol). There were no gender 
differences in relation to BP control; however, low- density 
lipoprotein cholesterol (LDL- C) and non HDL- C were 
better managed in men (see table 5).
Prescribing
Prescribing (table 1) was, on the whole, very good with 
85% or more of patients reporting taking antiplatelets, 
statins and BP- lowering drugs. However, despite more 
than 90% of patients prescribed BP- lowering drugs, less 
than three- quarters were at the JBS3 goal. This propor-
tion was much lower (43.2%) if a target of 130/80 mm 
Hg is used, which is in keeping with recent guidelines.14 15 
There is a similar picture for lipid control with less than 
half at goal despite 83% of patients being prescribed lipid- 
lowering drugs. In patients with self- reported diabetes at 
interview, glycaemic control was not at target in one- third 
of patients. Statins were less frequently prescribed in 
women (86.2% men, 80.3% women, p=0.02).
dIsCussIOn
Our A-3- P survey investigated the implementation of CVD 
prevention guidelines in the UK and continues to high-
light the enormous potential to reduce the risk of recur-
rent disease and associated disabilities and also to improve 
survival. In this discussion, we focus on achievement of 
a healthy lifestyle, treating risk factors—BP, lipids and 
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Table 2 Characteristics of patients advised to attend, participated if advised and who participated overall in a cardiac 
rehabilitation programme
Patient group
Advised to participate Participated if advised Participated overall
n/N (%) P value n/N (%) P value n/N (%) P value
All patients 944/1168 (80.8) 800/944 (84.8) 800/1168 (68.5)
Age <60 254/296 (85.8) 0.01 213/254 (83.9) 0.65 213/296 (72.0) 0.14
Age ≥60 690/872 (79.1) 587/690 (85.1) 587/872 (67.3)
Male 735/897 (81.9) 0.08 629/735 (85.6) 0.18 629/897 (70.1) 0.03
Female 209/271 (77.1) 171/209 (81.8) 171/271 (63.1)
AMI (STEMI) 213/242 (88.0) <0.001 180/213 (84.5) 0.15 180/242 (74.4) <0.001
AMI (non- STEMI) 428/514 (83.3) 356/428 (83.2) 356/514 (69.3)
CABG 99/107 (92.5) 87/99 (87.9) 87/107 (81.3)
PTCA 153/218 (70.2) 128/153 (83.7) 128/218 (58.7)
Unstable angina 51/87 (58.6) 49/51 (96.1) 49/87 (56.3)
AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; STEMI, 
ST- elevation myocardial infarction.
diabetes—to targets with cardioprotective medications, 
and the role of prevention and rehabilitation programmes.
Persistent smoking in those who were smoking at the time 
of their event is high at 45%. There is a lack of support in 
hospital and after discharge to help patients quit smoking 
or to maintain abstinence due to underprescribing of drugs 
and provision of counselling to support smoking cessation. 
Many of these persistent smokers intend to quit so there is 
the opportunity for a behavioural intervention supported 
by pharmacotherapies with proven efficacy,16 17 effective-
ness18 and safety19 in this patient population. Some patients 
were prescribed nicotine replacement therapy at the time 
of discharge from hospital but what is required is a system-
atic evidence- based approach which starts on the first day of 
hospital admission and continues after discharge in the CR 
programme and in general practice. The recent announce-
ment by the Department of Health to support smokers 
admitted to hospital to quit will improve smoking cessation 
rates including for those with coronary disease.20
Encouragingly, more than half of the interviewed patients 
reported taking regular exercise and one- fifth report that 
they intended to start doing so within the next 6 months. 
Taking regular exercise was more common in men; 
however, the older age of female patients and their associ-
ated disabilities should be taken into account. Interestingly, 
patients not achieving the physical activity target were less 
likely to be advised to attend CR, and were also less likely 
to attend a programme, and yet these patients would derive 
even greater benefits from supervised exercise sessions.
There is a high prevalence of obesity and central 
obesity in this population, particularly in women. About 
two- thirds were advised to lose weight, which means that 
such advice was not given to a significant minority, and 
a similar proportion reported they were attempting to 
do so. One caveat is that for those who successfully quit 
smoking, weight gain is common21 and this may be a 
confounding factor in this overall picture.
The high prevalence of central obesity is a major factor 
in the increasing prevalence of diabetes in patients with 
CHD. Diabetes is commonly associated with coronary 
disease and, as the results of the OGTT demonstrate 
there is a considerable overlap with two- thirds of patients 
with CHD exhibiting some form of dysglycaemia. What 
is of great concern is that two- thirds of these patients 
with dysglycaemia had not been identified at the time 
of their event or subsequently. Diabetes is a major risk 
factor for coronary disease and patients with both CHD 
and diabetes are at much greater risk of a further major 
adverse cardiovascular event. So why are we not screening 
the population with CHD without self- reported diabetes 
with an OGTT, the only test which most reliably identi-
fies all patients with diabetes and with impaired glucose 
tolerance?22 The identification of dysglycaemia will be a 
stimulus to greater diligence in monitoring for the devel-
opment of diabetes, and in those with newly diagnosed 
diabetes, appropriate monitoring for the development 
of microvascular disease and other complications can be 
put in place.
Although cardioprotective medications are prescribed 
in all patients, the extent to which risk factors are 
controlled to national targets remains disappointing. 
Just over two- thirds of patients are achieving the conser-
vative BP target of <140 mm Hg and/or 90 mm Hg, but 
only 42% are achieving the target of <130 mm Hg and/
or 80 mm Hg. The non- HDL- C target of <2.5 mmol/L is 
achieved by just over half of all patients and only 44% are 
below the more stringent LDL- C target of <1.8 mmol/L. 
In patients with self- reported diabetes an HbA1c <7.0% is 
achieved in just over half of all patients. In these patients 
with diabetes the lower BP target of <130 mm Hg and/or 
80 mm Hg is only achieved by just over a third.
After experiencing an acute cardiac event and/or under-
going a revascularisation procedure, patients require an 
interdisciplinary CR programme which provides expert 
 on M















7Jennings CS, et al. Open Heart 2020;7:e001196. doi:10.1136/openhrt-2019-001196
Cardiac risk factors and prevention
Table 3 Lifestyle habits and change attempts in patients 
participating in the A-3- P survey
Men % Women % All %
Tobacco
Referred to specialist clinic 32.7 40.4 34.6
Advised to stop
  Use NRT 34.4 50.0 (p=0.04) 38.1
  Use bupropion 2.6 2.0 2.5
  Use varenicline 5.9 3.9 5.4
Made quit attempt 60.1 71.7 63
Tried to reduce 37.5 26.4 34.7
Attended specialist clinic 14.4 11.3 13.6
Used NRT 23.8 24.5 23.9
Used bupropion 0.0 1.9 0.5
Used varenicline 3.3 1.9 2.9
Diet and weight
Dietary advice 75.4 71.5 74.5
Advised to lose weight 63.7 59.4 62.7
Steps taken—improve diet
  Reduce salt 67.2 60.5 (p=0.04) 65.7
  Reduce fat 69.2 69.5 69.2
  Change fat 61.6 60.3 61.3
  Increase fruits and 
vegetables
72.9 65.7 (p=0.02) 71.2
  Eat more fish 61.3 56.4 60.1
  Reduce sugar 64.7 55.9 (p=0.009) 62.6
  Reduce alcohol 51.6 40.7 (p=0.002) 49.1
  Eat more sterols 29.4 17.1 (p<0.001) 26.5




Disability/infirmity 38.1 51.1 (p<0.001) 41.1
Infirmity limits activity 74.6 85 (p=0.01) 77.6
Professional advice to 
increase activity
52.4 57.1 53.5
Advised to increase everyday 
activities
60.6 59.9 17.2
Advised to join walking group 16.8 18.3 68.8
Any steps taken to increase 
activity
70.7 71.2 70.8
A-3- P, ASPIRE-3- PREVENT; NRT, nicotine replacement therapy.
Table 4 Prescription of tobacco cessation drugs at 










NRT 27 (17.8) 14 (28.6) 41 (20.4)
Bupropion 1 (0.7) 1 (2) 2 (1)
Varenicline 1 (0.7) 1 (2) 2 (1)
Interview NRT 10 (6.1) 1 (1.9) 11 (5.1)
Bupropion 0 (0) 0 (0) 0 (0)
Varenicline 0 (0) 0 (0) 0 (0)
NRT, nicotine replacement therapy.
Figure 2 Self- reported regular planned exercise.
support to help patients and families change adverse 
health behaviours, to monitor and manage medical risk 
factors to targets and promote adherence to prescribed 
medications over the long term. Such a programme 
should be an integral part of their care with patients 
moving seamlessly from acute care to longer term preven-
tive care to further reduce their risk of events, the need 
for further revascularisation and to improve survival. 
In this survey, 68% participated in some form of CR 
programme by comparison with 47% reported by NACR, 
and therefore our patient sample is skewed towards those 
undertaking rehabilitation. Participation was higher 
for younger patients, men and those who had a CABG. 
Although these patients all had coronary atherosclerosis 
there was a large differential in participation rates from 
81% for CABG to 56% for those presenting with acute 
myocardial ischaemia. Older patients and women were 
less likely to be advised to attend a programme and the 
same was true for patients with acute myocardial isch-
aemia. There should be no difference in participation 
rates by diagnostic category or gender given that they all 
have the same underlying disease.
A recent systematic review and meta- analysis of trials 
since 2010 of prevention and rehabilitation programmes 
showed no overall benefit in terms of all- cause mortality, 
but significant reductions in cardiovascular mortality, 
including stroke.23 However, comprehensive programmes 
managing six or more risk factors did reduce all- cause 
mortality, compared with programmes managing less 
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Figure 3 Glucose metabolism in 1177 patients based on 
an oral glucose tolerance test in those without self- reported 
diabetes.
Table 5 Therapeutic control of blood pressure, cholesterol and glucose by gender
Male (n=903) Female (n=274)
P valuen % (95% CI) n % (95% CI)
Blood pressure* 899 258
  BP at target 1† 595 69.9 (66.7 to 73.0) 187 72.4 (66.6 to 77.8) 0.43
  BP at target 2‡ 360 42.3 (39.0 to 45.7) 119 46.1 (39.9 to 52.4) 0.28
Cholesterol§ 759 219
  TC <5.0 mmol/L 698 92.0 (89.8 to 93.8) 184 84.0 (78.5 to 88.6) <0.001
  TC <4.0 mmol/L 523 68.9 (65.4 to 72.2) 104 47.5 (40.7 to 54.3) <0.001
  LDL <1.8 mmol/L¶ 329 43.9 (40.3 to 47.6) 75 34.7 (28.4 to 41.5) 0.02
  LDL <2.0 mmol/L¶ 441 58.9 (55.3 to 62.4) 93 43.1 (36.4 to 49.9) <0.001
  LDL <3.0 mmol/L¶ 695 92.8 (90.7 to 94.5) 193 89.4 (84.5 to 93.1) 0.10
  Non- HDL <2.5 mmol/L 400 52.7 (49.1 to 56.3) 89 40.6 (34.1 to 47.4) 0.002
Glucose and BP control in diabetics** 209 58
  Glucose <7 mmol/L†† 61 30.4 (24.1 to 37.2) 16 29.1 (17.6 to 42.9) 0.86
  HbA1c <7% (<53 mmol/mol)‡‡ 107 54.9 (47.6 to 62.0) 29 50.0 (36.6 to 63.4) 0.51
  HbA1c <6% (<42 mmol/mol)‡‡ 29 14.9 (10.2 to 20.7) 9 15.5 (7.3 to 27.4) 0.90
  BP at target‡ 81 38.8 (32.1 to 45.7) 25 43.1 (30.2 to 56.8) 0.55
p values in bold indicate those with statistical significance
*Figures for those on blood pressure- lowering medication.
†Defined as blood pressure <140/90 mm Hg.
‡Defined as blood pressure <130/80 mm Hg.
§Figures for those on lipid- lowering medication and with cholesterol measurements made.
¶Data available for 749 male and 216 female patients.
**Figures for self- reported diabetics only.
††Data available for 201 male patients, 55 female.
‡‡Data available for 195 male patients, 58 female.
BP, blood pressure; HDL, high- density lipoprotein; LDL, high- density lipoprotein; TC, total cholesterol.
than six risk factors. Programmes that took responsibility 
for prescribing, uptitrating and monitoring adherence 
to cardioprotective medications also reduced all- cause 
mortality compared with programmes that devolved that 
responsibility to other healthcare professionals. These 
results support the view that prevention and rehabil-
itation programmes should be truly comprehensive, 
addressing lifestyle, risk factor management and taking 
responsibility within the service provided to manage all 
cardioprotective medications.24 25
Exercise- based CR is not truly comprehensive based on 
the results of this survey. Achievement of physical activity 
guidelines is better in those attending CR but there is no 
impact on persistent smoking, the prevalence of obesity 
and central obesity or control of BP to defined targets. 
Achievement of the LDL- C goal is significantly better in 
those attending CR but even so more than half of these 
patients are not achieving this target. Diabetes control is 
no better in those attending CR and new diabetes was 
missed just as frequently in those attending CR compared 
with those who did not. Cardioprotective medications 
were prescribed as commonly in those attending and not 
attending CR apart from antiplatelet medications which 
were significantly higher in those attending CR. Anxiety 
and depression outcomes were no different and health- 
related quality of life was the same. To reduce the risk of 
a further event and improve life expectancy, it is essential 
to address all aspects of lifestyle, manage the biological 
risk factors to targets and ensure adherence with opti-
mally prescribed cardioprotective medications.
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Cardiac risk factors and prevention
The availability and quality of these programmes 
should be ensured through appropriate funding and 
support from the Department of Health and auditing 
their adherence to all BACPR exemplary standards and 
core components. The ongoing National Audit of Cardiac 
Rehabilitation does not reflect all these standards and in 
particular there is no adequate audit of risk factors (BP, 
lipids and diabetes) or cardioprotective medications. 
NACR should consider expanding its audit function to 
embrace CVD as a whole and all important aspects of 
secondary prevention to become the National Audit for 
Cardiovascular Disease Prevention and Rehabilitation. 
The current NACR certification programme is also not 
comprehensive and BACPR and NACR should work 
together to develop performance levels which reflect the 
overall BACPR standards as a basis for certification.
strengths
The main strength of A-3- P is the real- world national 
setting of this survey, together with the standardised meth-
odology used to interview and examine patients using the 
same instruments (measuring stick, scales, tape measure 
and BP machine), the HemoCue point- of- care device for 
glucose measurement and a central laboratory for a full 
lipid profile, glucose, HbA1c and creatinine. All patients 
without self- reported diabetes were systematically investi-
gated with an OGTT and therefore the metabolic status 
of all patients with CHD is described. The generic names 
and total daily doses of all prescribed drugs at hospital 
discharge and again at follow- up are recorded together 
with a measure of adherence.
limitations
This survey of patients with CHD is based on a conven-
ience sample of specialist cardiac centres and district 
general hospitals across the UK, with most centres 
located in England, followed by Scotland and fewer in 
Wales and Northern Ireland, which may not be represent-
ative of all hospitals. A systematic retrospective sample of 
consecutive patients from hospital databases was identi-
fied, but the patient response rate to interview and exam-
ination was very low, a source of potential bias. The high 
proportion of patients attending CR, 69% in our survey 
compared with 47% in the NACR database, indicates a 
bias towards healthier patients attending rehabilitation 
and therefore our results overestimate the health status 
of all patients with CHD and their quality of care in terms 
of risk factor control and drug prescribing. A truly repre-
sentative patient sample is likely to include more higher 
risk patients with less healthier lifestyles and even poorer 
standards of secondary preventive care. Self- reported 
lifestyle has limitations but smoking habit was validated 
by breath carbon monoxide, and validated tools were 
used to measure physical activity and exercise. Diet could 
not be assessed using validated methods as these are too 
complex and time consuming and beyond the capacity of 
this survey.
COnClusIOn
The overall standard of preventive care remains subop-
timal in the UK for patients with CHD. Although over 
two- thirds accessed a CR programme, inequalities still 
exist with less female, older adults and some diagnostic 
groups not attending. Despite CR attendance, lifestyle 
and risk factor management for several factors remains 
inadequate among attenders, reflecting the content 
and resources for these programmes. Patients require a 
comprehensive preventive cardiology programme with 
interdisciplinary expertise to address lifestyle, risk factor 
management and adherence to cardioprotective medica-
tions in order to achieve the standards and the specified 
core components set out by the BACPR and JBS3 guide-
lines.
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